BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22431535)

  • 21. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
    Cappellesso R; Fassan M; Hanspeter E; Bornschein J; d'Amore ES; Cuorvo LV; Mazzoleni G; Barbareschi M; Pizzi M; Guzzardo V; Malfertheiner P; Micev M; Guido M; Giacomelli L; Tsukanov VV; Zagonel V; Nitti D; Rugge M
    Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
    Shan L; Ying J; Lu N
    Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
    Hechtman JF; Polydorides AD
    Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.
    Koopman T; Smits MM; Louwen M; Hage M; Boot H; Imholz AL
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1343-51. PubMed ID: 25544671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
    Powell WC; Hicks DG; Prescott N; Tarr SM; Laniauskas S; Williams T; Short S; Pettay J; Nagle RB; Dabbs DJ; Scott KM; Brown RW; Grogan T; Roche PC; Tubbs RR
    Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):94-102. PubMed ID: 17536315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
    McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
    Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical significance of HER2 positivity in gallbladder adenocarcinoma].
    Yao JG; Wang CH; Liu Y
    Zhonghua Bing Li Xue Za Zhi; 2017 Apr; 46(4):245-248. PubMed ID: 28376590
    [No Abstract]   [Full Text] [Related]  

  • 29. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
    Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
    Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.
    Yoon HH; Sukov WR; Shi Q; Sattler CA; Wiktor AE; Diasio RB; Wu TT; Jenkins RB; Sinicrope FA
    Cancer; 2014 Feb; 120(3):415-24. PubMed ID: 24151090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma.
    Lucas E; Jabbar SB; Molberg K; Fang Y; Xie XJ; Blacketer S; Sahoo S
    Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):403-409. PubMed ID: 31233398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
    Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
    Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
    Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
    BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory.
    Jedrzkiewicz J; Sirohi D; Uvejzovic N; Gulbahce HE
    Mod Pathol; 2022 Apr; 35(4):549-553. PubMed ID: 34663915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.
    Hu Y; Bandla S; Godfrey TE; Tan D; Luketich JD; Pennathur A; Qiu X; Hicks DG; Peters JH; Zhou Z
    Mod Pathol; 2011 Jul; 24(7):899-907. PubMed ID: 21460800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience.
    Tubbs RR; Hicks DG; Cook J; Downs-Kelly E; Pettay J; Hartke MB; Hood L; Neelon R; Myles J; Budd GT; Moore HC; Andresen S; Crowe JP
    Diagn Mol Pathol; 2007 Dec; 16(4):207-10. PubMed ID: 18043283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients.
    Sornmayura P; Rerkamnuaychoke B; Jinawath A; Euanorasetr C
    J Med Assoc Thai; 2012 Jan; 95(1):88-95. PubMed ID: 22379747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification.
    Abdelhakeem A; Wang X; Rogers JE; Trail A; Zhao M; Blum-Murphy M; Estrella JS; Ajani JA
    Oncology; 2020; 98(12):884-888. PubMed ID: 32998149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.